The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Abstract
UNLABELLED: The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, (68)Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)]) was developed as a PSMA ligand. The aim of this study was to investigate the detection rate of (68)Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy. METHODS: Two hundred forty-eight of 393 patients were evaluable for a retrospective analysis. Median prostate-specific antigen (PSA) level was 1.99 ng/mL (range, 0.2-59.4 ng/mL). All patients underwent contrast-enhanced PET/CT after injection of 155 ± 27 MBq of (68)Ga-PSMA ligand. The detection rates were correlated with PSA level and PSA kinetics. The influence of antihormonal treatment, primary Gleason score, and contribution of PET and morphologic imaging to the final diagnosis were assessed. RESULTS: Two hundred twenty-two (89.5%) patients showed pathologic findings in (68)Ga-PSMA ligand PET/CT. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of ≥2, 1 to <2, 0.5 to <1, and 0.2 to <0.5 ng/mL, respectively. Whereas detection rates increased with a higher PSA velocity (81.8%, 82.4%, 92.1%, and 100% in <1, 1 to <2, 2 to <5, and ≥5 ng/mL/y, respectively), no significant association could be found for PSA doubling time (82.7%, 96.2%, and 90.7% in >6, 4-6, and <4 mo, respectively). (68)Ga-PSMA ligand PET (as compared with CT) exclusively provided pathologic findings in 81 (32.7%) patients. In 61 (24.6%) patients, it exclusively identified additional involved regions. In higher Gleason score (≤7 vs. ≥8), detection efficacy was significantly increased (P = 0.0190). No significant difference in detection efficacy was present regarding antiandrogen therapy (P = 0.0783). CONCLUSION: Hybrid (68)Ga-PSMA ligand PET/CT shows substantially higher detection rates than reported for other imaging modalities. Most importantly, it reveals a high number of positive findings in the clinically important range of low PSA values (<0.5 ng/mL), which in many cases can substantially influence the further clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
(1997) · PubMed · Cited by 1,541
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Self-citationAfshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Self-citationTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.-E., Wängler, C., Mier, W., Haberkorn, U., & Eisenhut, M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200279b · Cited by 843
Self-citationSweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 513
Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Mehes, G. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 384
Krause, B. J., Souvatzoglou, M., Tuncel, M., Herrmann, K., Buck, A. K., Praus, C., Schuster, T., Geinitz, H., Treiber, U., & Schwaiger, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0581-4 · Cited by 367
Self-citationAfshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M., & Zechmann, C. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2069-0 · Cited by 325
Self-citationCimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
Husarik, D. B., Miralbell, R., Dubs, M., John, H., Giger, O. T., Gelet, A., Cservenyàk, T., & Hany, T. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0552-9 · Cited by 295
Jager, G. J., Barentsz, J. O., Oosterhof, G. O., Witjes, J. A., & Ruijs, S. J. (1996) · American Journal of Roentgenology · doi:10.2214/ajr.167.6.8956585 · Cited by 259
Oyen, R. H., Van Poppel, H. P., Ameye, F. E., Van de Voorde, W. A., Baert, A. L., & Baert, L. V. (1994) · Radiology · doi:10.1148/radiology.190.2.8284375 · Cited by 198
Heinisch, M., Dirisamer, A., Loidl, W., Stoiber, F., Gruy, B., Haim, S., & Langsteger, W. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0023-2 · Cited by 191
Brogsitter, C., Zöphel, K., & Kotzerke, J. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2358-2 · Cited by 134
Technology Insight: monoclonal antibody imaging of prostate cancer
Bander, N. H. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0452 · Cited by 130
Radionuclide and hybrid imaging of recurrent prostate cancer
Beer, A. J., Eiber, M. J., Souvatzoglou, M., Schwaiger, M., & Krause, B. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70103-0 · Cited by 104
Self-citationManagement of recurrent disease after radical prostatectomy
Bott, S. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500732 · Cited by 90
Yoshida, S., Nakagomi, K., 後藤, 修., Futatsubashi, M., & Torizuka, T. (2005) · Urologia Internationalis · doi:10.1159/000083551 · Cited by 83
Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer
Noss, K. R., Wolfe, S. A., & Grimes, S. R. (2002) · Gene · doi:10.1016/s0378-1119(02)00397-9 · Cited by 80
Poppel, H. V., Vekemans, K., Pozzo, L. D., Bono, A. V., Kliment, J., Montironi, R., Debois, M., & Collette, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.030 · Cited by 77
Cited by
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 832
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H.-J., Heck, M., Kübler, H., Beer, A. J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 779
Self-citationFendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779
Self-citation
Metadata
- Authors
- Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., Wester, H.-J., Gschwend, J. E., & Schwaiger, M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2015-03-19
- Volume
- 56
- Issue
- 5
- Pages
- 668-674
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2137670219
- Cited by
- 994
- References
- 26
- FWCI
- 121.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.